Jump to content

Drilldown: Medicines

Pharmacopedia
BrowseCategoriesLog in

Choose a table:


Medicines > classes : Anti-amyloid beta (Aβ) monoclonal antibody or Classic Psychedelic or Neuroleptic

Use the filters below to narrow your results.

generic:
None (3)
brand:
None (69) · Aduhelm (1) · Delysid (historical, Sandoz, withdrawn 1965) (1) · Fanapt (1) · Geodon (1) · Inapsine (1) · Invega (1) · Kisunla (1) · Latuda (1) · Leqembi (1) · Loxitane (1) · Mellaril (1) · Moban (1) · Navane (1) · Orap (1) · Prolixin (1) · Saphris (1) · Stelazine (1) · Thorazine (1) · Trilafon (1)
classes: (Click arrow to add another value)
mechanism:
5-HT2A agonist (26) · Potent 5-HT2A agonist (5) · LSD analogue; 5-HT2A agonist (4) · Phenothiazine D2 antagonist (4) · Prodrug of LSD; 5-HT2A agonist (4) · None (2) · Contains LSA (2) · Contains mescaline (2)
uses:
None (85) · Alzheimer disease (FDA accelerated approval June 2021; '''withdrawn from market January 2024''' by manufacturer Biogen). At time of approval indicated for MCI or mild dementia stage of AD. (1) · Alzheimer disease (MCI or mild dementia stage), FDA-approved July 2024 (1) · Alzheimer disease (MCI or mild dementia stage); FDA accelerated approval Jan 2023 → traditional approval July 2023 (1)
starting dose:
None (85) · 10 mg/kg IV every 2 weeks (1) · 700 mg IV q4w × 3 doses, then 1400 mg IV q4w; may discontinue when amyloid PET shows clearance (1) · Was 1 mg/kg IV q4w × 2, then 3 mg/kg × 2, then 6 mg/kg × 2, then 10 mg/kg q4w (1)
preparations:
None (85) · 200 mg/2 mL, 500 mg/5 mL vials for IV infusion (1) · 350 mg/20 mL vial for IV infusion (1) · Was: 170 mg/1.7 mL, 300 mg/3 mL vials for IV infusion (1)
fda max:
None (85) · 10 mg/kg q2w (1) · 1400 mg q4w (1) · Withdrawn 2024 (1)
routes:
None (84) · IV infusion (60 min) every 2 weeks; outpatient or infusion-center setting (1) · IV infusion every 4 weeks (2) · Oral (1)
onset:
None (84) · 30–60 minutes (1) · Amyloid PET clearance within months; cognitive benefit over 18 months (1) · PET Aβ reduction over months (1) · Slowing of cognitive decline over 18 months (modest effect, ~27% relative slowing) (1)
duration:
None (84) · 8–12 hours (1) · Ongoing dosing (1) · Treatment can be discontinued upon achieving amyloid clearance (1) · Withdrawn (1)
halflife:
None (84) · 3–5 hours (1) · ~12.1 days (1) · ~25 days (1) · ~5-7 days (1)
bioavailability:
None (84) · 100% (IV) (3) · 70–90% (oral) (1)
pregnancy:
None (84) · Discontinued/withdrawn (1) · Limited data (2) · Not established (1)
legal:
None (84) · Rx; ARIA monitoring required (1) · Rx; REMS-like program for ARIA monitoring (1) · Schedule I (United States) (1) · Withdrawn from US market January 2024 (1)

Showing below up to 88 results in range #1 to #88.

View (previous 250 | next 250) (20 | 50 | 100 | 250 | 500)


View (previous 250 | next 250) (20 | 50 | 100 | 250 | 500)

Retrieved from "https://pharmacopedia.wiki/p/Special:Drilldown/Medicines"